logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Yancoal Australia (03668) appoints Sharif Brar as Chief Executive Officer

date
26/08/2025
The China Fortune Financial APP news, Yancoal Australia (03668) announced the appointment of Mr. Sharif Burra as the new CEO of Yancoal Australia, effective from September 8, 2025. Mr. Yue Ning will no longer serve as the acting CEO of the company, effective from September 8, 2025.
Latest
3 m ago
Daquan New Energy announces buyback of $1 billion worth of stocks.
3 m ago
Daquan New Energy announced a buyback of $100 million in shares.
4 m ago
Every AI Express, Tianfeng Securities released a research report on August 26 giving a buy rating to Dayuan Pump Industry (603757.SH). The rating reasons mainly include: 1) development of various sectors is promising, and new businesses are starting to gain volume; 2) profit fluctuates, with non-recurring projects affecting net profit; 3) the market space for liquid cooling pumps is vast, as a key competitive track in AI computing power infrastructure, the liquid cooling industry is developing rapidly. (Daily Economic News)
4 m ago
On Tuesday, the Lilly Company stated that its daily weight loss pill helped obese and type 2 diabetes patients lose weight in late-stage trials, meeting the main goal of the study and paving the way for the company to seek approval for the drug globally. This treatment method is gradually becoming a new needle-free alternative in the lucrative market of GLP-1s for weight loss and diabetes medications. The more convenient pill form can increase the supply of treatment and is easier to obtain compared to the expensive weekly injections that currently dominate the field. Unlike similar oral treatments from main competitor Novo Nordisk, Lilly's pill does not require dietary restrictions. In a 72-week trial, the highest dose of the oral medication orforglipron helped patients on average lose 10.5% of their weight (approximately 10.4 kilograms), while patients taking a placebo only lost 2.2%. If all patients (including dropouts) are included in the analysis, the weight loss effect of the drug is 9.6%.
4 m ago
Lei Lai diet pill orforglipron late-stage trials meet standards, paving the way for global approval.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.